TRVN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
Dzisiejszy wolumen	42 532.00
Średni wolumen	204 957
Kapitalizacja rynkowa	7.42M
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $-0.370 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (2.39%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.75
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

Wolumen Korelacja

Długi: -0.20 (neutral)

Krótki: -0.88 (strong negative)

Signal:(52.298) Neutral

Trevena Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevena Inc Korelacja - Waluta/Towar

-0.15
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.32
( neutral )

Trevena Inc Finanse

Annual	2023
Przychody:	$3.13M
Zysk brutto:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2023
Przychody:	$3.13M
Zysk brutto:	$562 000 (17.98 %)
EPS:	$-3.16

FY	2022
Przychody:	$-418 000
Zysk brutto:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
Przychody:	$567.00
Zysk brutto:	$-387.00 (-68.25 %)
EPS:	$-0.0101

Financial Reports:

No articles found.

Trevena Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Aktualne aktualizacje dla Trevena Inc [TRVN]

Upcoming Earnings Alert

Trevena Inc Options Data

Calls

Puts